venetoclax
Showing 1 - 5 of 5
Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia Trial in Kunming (Experimental: Venetoclax in combination
Not yet recruiting
- Elderly AML Patients
- +4 more
- Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
- Active Comparator: Standard dose of Venetoclax + Azacitidine
-
Kunming, Yunnan, ChinaThe Second Affiliated Hospital of Kunming Medical University.
Oct 3, 2023
Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax Trial (Venetoclax, Dexamethasone Oral)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- +2 more
- Venetoclax
- Dexamethasone Oral
- (no location specified)
Aug 16, 2023
Acute Myeloid Leukemia, Venetoclax Trial in Kunming (combination of venetoclax and HAA regimen)
Recruiting
- Acute Myeloid Leukemia
- Venetoclax
- combination of venetoclax and HAA regimen
-
Kunming, Yunnan, ChinaThe Second Affiliated Hospital of Kunming Medical University.
May 29, 2023
Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)
Recruiting
- Hypomethylating Agent
- +2 more
- Venetoclax
- Azacitidine or decitabine
-
Shanghai, Shanghai, ChinaShanghai Jiao Tong University School of Medicine Affilated Shang
May 2, 2023
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute
Recruiting
- Acute Myeloid Leukemia, Adult
- +2 more
-
Trieste, ItalySC Ematologia Ospedale Maggiore
Sep 14, 2020